Independent Market Access and Reimbursement Risk Assessment.
Built by former payers, HTA reviewers, and Industry Experts.
We have just published a MARA Rating for a preparative treatment used before stem cell transplants in blood cancers. The clinical question: does this improve survival compared to the established
Summary CVS Caremark will add Eli Lilly’s oral obesity medicine Foundayo to its formularies on June 1, 2026. Zepbound returns as a preferred option from October 1. Both changes reverse
A MARA Rating we completed for an Alzheimer’s treatment arrived with one of the highest public profiles in recent memory. The phase 3 trial showed meaningful slowing of cognitive decline.
AstraZeneca received FDA approval on May 18, 2026, for Baxfendy, the first aldosterone synthase inhibitor cleared for adults with uncontrolled hypertension. Click here to go to our independent assessment. https://mararating.com/report/baxdrostat-for-treatment-resistant-hypertension-as-of-april-2026/The
We have just published a MARA Rating for a maintenance treatment in lung cancer. The trial answered one question clearly: does this treatment extend survival? It does. Patients lived longer
In HTA-driven environments, stability in reimbursement positioning often reflects persistence of structural constraints rather than absence of progress. Following a structured surveillance reassessment, the MARA Rating for baxdrostat in treatment-resistant
1. Executive Summary During April 2026, MARA issued 12 rating actions across multiple therapeutic areas. The monthly distribution was concentrated in B+ (Very Weak) and B++ (Marginal), with no A-range,
MARA rated sebetralstat (Ekterly) B++ (Marginal) before the G-BA published Beschluss 7763 on 2 April 2026. The G-BA recognized a non-quantifiable additional benefit under the orphan drug pathway — placing
Executive Summary MARA is currently finalizing a series of reimbursement risk assessments across twelve drug–indication pairs spanning oncology, rare diseases, immunology, nephrology, and cardiovascular conditions. These assessments have been initiated
MARA rated linvoseltamab (Lynozyfic) B+ (Very Weak) before the G-BA published Beschluss 7730 on 19 March 2026. The B+ signal was driven by two structurally weak decision-critical domains: no HRQoL